Cancer treatment is a complex and challenging endeavor, often requiring patients to manage multiple medications simultaneously. This can lead to a higher risk of drug interactions and other complications. As a result, scientists are actively seeking innovative solutions that can address multiple health issues with a single compound, potentially improving treatment effectiveness and reducing the likelihood of resistance. Researchers at Kaunas University of Technology (KTU) have made a significant breakthrough in this area by developing hybrid compounds that simultaneously target cancer cells and inhibit the growth of bacteria and fungi. These compounds, known as hybrid molecules, combine two or more active structures capable of acting on different biological targets, potentially increasing treatment effectiveness and reducing the risk of resistance. The development of such compounds is driven by two major challenges in modern medicine: aggressive forms of cancer and the growing issue of antimicrobial resistance. The study, published in the scientific article "New hybrid pyridine–1,2,4-triazole scaffolds: synthesis, in vitro evaluation of anticancer and antimicrobial activity, and in silico insights," evaluated the potential of these compounds using cells from aggressive forms of cancer, including lung cancer, triple-negative breast cancer, and melanoma. The results were promising, with some compounds reducing cancer cell viability and showing strong activity against bacteria and fungi. One compound, in particular, outperformed currently used drugs in terms of antifungal activity, while its antibacterial activity was comparable to that of the antibiotic vancomycin. The researchers were surprised to find that the compound with the strongest dual action was not the one they had expected to perform best, highlighting the importance of every stage of research in drug development. While these findings are an important step forward, there is still a long way to go before any potential drug can be developed. The next stages will involve a more detailed investigation of the mechanisms of action of the most promising compounds and their effects on healthy cells, followed by preclinical and clinical studies and further optimization of the molecules. The study was carried out as part of the project PYRANCAM, funded by the Research Council of Lithuania under the Researcher Groups funding scheme. The results presented in the article build on previous research and contribute to international efforts in medicinal chemistry to find new solutions for treating cancer and combating antimicrobial resistance. This research highlights the potential of hybrid compounds in addressing multiple health issues simultaneously and the importance of continued scientific exploration in this field.
